©2024 Stanford Medicine
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Not Recruiting
Trial ID: NCT00537056
Purpose
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).
Official Title
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Stanford Investigator(s)
Robert Herfkens
Professor of Radiology (Cardiovascular Imaging), Emeritus
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:- Measurable disease by RECIST criteria
* Pathologic diagnosis of renal cell cancer
* Advanced (stage IV) renal cell cancer
* Karnofsky performance status of (KPS\>70)
* Consent to participate in the clinical trial Exclusion Criteria:- Patients who cannot complete a PET/CT scan.
* Pregnant women.
* Healthy volunteers.
* Patients participating in other research protocols will be excluded from this study.
* Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications for MRI.
Intervention(s):
procedure: FDG PET CT
procedure: DCE MRI
drug: F-18 Fluoro-deoxi-glucose
drug: Gadolinium-DTPA
drug: Sunitinib
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Andrew Quon
6507361369